How biopharma is meeting the next payer challenge
With their higher costs co-pay accumulators could be a step backwards for reducing patients' drug price burden.
As US hospitals consolidate their pharmacy muscles grow
Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.
Calling time on biotech’s shady stock-promotion schemes
The US regulator has come down surprisingly hard on biotech stock promotion schemes.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.